Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients
NCT ID: NCT02169141
Last Updated: 2014-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2012-11-30
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PK of Levofloxacin in MDR-TB Patients
NCT03000517
Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
NCT01918397
Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia
NCT00306319
Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients
NCT01055145
Pharmacokinetics and Safety of Moxifloxacin
NCT01329250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PK of Levofloxacin-Capreomycin
Pharmacokinetics (PK) in M/XDR-TB patients receiving at least Levofloxacin and Capreomycin as part of their WHO treatment for M/XDR-TB
Pharmacokinetics
multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pharmacokinetics
multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* culture positive
* diagnosis of MDR-TB
Exclusion Criteria
* Pregnancy
* allergy to IV canula material
* insertion of IV canula not possibele
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Republican Scientific and Practical Centre for Pulmonology and TB
UNKNOWN
National Institute for Public Health and the Environment (RIVM)
OTHER_GOV
University Medical Center Groningen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
JWC Alffenaar
PhD PharmD Clinical Pharmacologist Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JW C Alffenaar, PhD PharmD
Role: PRINCIPAL_INVESTIGATOR
UMCG
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Republican Scientific and Practical Center for TB and Pulmonology
Minsk, , Belarus
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Van't Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, van der Laan T, Kosterink JGW, van der Werf TS, van Soolingen D, van den Hof S, Skrahina A, Alffenaar JC. Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00343-17. doi: 10.1128/AAC.00343-17. Print 2017 Aug.
Velasquez AMA, Ribeiro WC, Venn V, Castelli S, Camargo MS, de Assis RP, de Souza RA, Ribeiro AR, Passalacqua TG, da Rosa JA, Baviera AM, Mauro AE, Desideri A, Almeida-Amaral EE, Graminha MAS. Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00688-17. doi: 10.1128/AAC.00688-17. Print 2017 Aug.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LC-20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.